Scholarlink

Background <p>Accurately assessing chemosensitivity to drugs such as cisplatin is crucial for optimizing outcomes of high-grade serous ovarian carcinoma (HGSOC) patients. Developing prediction models and identifying biomarkers can assist differentiate chemotherapy-sensitive from chemotherapy-resistant subtypes.</p> Methods <p>We integrated 908 transcriptome samples from 12 HGSOC datasets of GEO and TCGA across four detection platforms. Differentially ranked genes (DRGs) were identified by applying intra-sample rank transformation and performing T-test. To refine the selection of informative DRGs, a recurrent logistic regression (RLR) model was employed, followed by model optimization using the Pairwise Analysis of Gene Expression (PAGE) algorithm to establish clinically applicable gene pair signature.</p> Results <p>Kinesin Family Member 20&#xa0;A (KIF20A) and Chromogranin B (CHGB) were paired to establish a robust gene pair signature, KIF20A::CHGB Pair (KCP), which exhibited remarkable discriminant accuracy (Accuracy = 0.9397; AUROC = 0.9668; AUPRC = 0.9799) in distinguishing HGSOC from controls in eight independent validation cohorts. Further survival and functional analyses revealed that altered rank relationships between KIF20A and CHGB were significantly associated with prognosis and platinum resistance in HGSOC. Following exposure to standard chemotherapy regimens, we conducted RT-qPCR, CCK-8(Cell Counting Kit-8) viability assays, EdU proliferation assays, flow cytometry, and SynergyFinder, which collectively assessed cellular proliferation and cell-cycle responses, demonstrating that both genes contribute comparably to the malignant phenotype.</p> Conclusions <p>Elevated KIF20A or CHGB expression drives chemoresistance and correlates with poor prognosis in HGSOC. Silencing either gene significantly enhances the growth‑inhibitory effects of cisplatin and other standard chemotherapeutic agents. Our findings establish KCP as a robust diagnostic and prognostic biomarker and highlight KIF20A and CHGB as synergistic targets for overcoming platinum resistance in ovarian cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Large-scale transcriptome analysis reveals KIF20A as a novel indicator of cisplatin resistance in high-grade serous ovarian cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月9日

查看全文
  • Lixin Cheng,
  • Xiao Wang,
  • Jie Zhang,
  • Qitai Cai,
  • Shishi Meng,
  • Jie Li,
  • Pingyue Yu,
  • Yifan Zhang,
  • Shaoxiang Wang,
  • Dapeng Hao,
  • Minge Li,
  • Haili Li

摘要

Background

Accurately assessing chemosensitivity to drugs such as cisplatin is crucial for optimizing outcomes of high-grade serous ovarian carcinoma (HGSOC) patients. Developing prediction models and identifying biomarkers can assist differentiate chemotherapy-sensitive from chemotherapy-resistant subtypes.

Methods

We integrated 908 transcriptome samples from 12 HGSOC datasets of GEO and TCGA across four detection platforms. Differentially ranked genes (DRGs) were identified by applying intra-sample rank transformation and performing T-test. To refine the selection of informative DRGs, a recurrent logistic regression (RLR) model was employed, followed by model optimization using the Pairwise Analysis of Gene Expression (PAGE) algorithm to establish clinically applicable gene pair signature.

Results

Kinesin Family Member 20 A (KIF20A) and Chromogranin B (CHGB) were paired to establish a robust gene pair signature, KIF20A::CHGB Pair (KCP), which exhibited remarkable discriminant accuracy (Accuracy = 0.9397; AUROC = 0.9668; AUPRC = 0.9799) in distinguishing HGSOC from controls in eight independent validation cohorts. Further survival and functional analyses revealed that altered rank relationships between KIF20A and CHGB were significantly associated with prognosis and platinum resistance in HGSOC. Following exposure to standard chemotherapy regimens, we conducted RT-qPCR, CCK-8(Cell Counting Kit-8) viability assays, EdU proliferation assays, flow cytometry, and SynergyFinder, which collectively assessed cellular proliferation and cell-cycle responses, demonstrating that both genes contribute comparably to the malignant phenotype.

Conclusions

Elevated KIF20A or CHGB expression drives chemoresistance and correlates with poor prognosis in HGSOC. Silencing either gene significantly enhances the growth‑inhibitory effects of cisplatin and other standard chemotherapeutic agents. Our findings establish KCP as a robust diagnostic and prognostic biomarker and highlight KIF20A and CHGB as synergistic targets for overcoming platinum resistance in ovarian cancer.